Annual Report 2019-20
Our Values
Our Partnership Commitment
Our Client Footprint
Our Business Divisions
active clients
collaborations with the top ten pharmaceutical companies
revenue for FY20
scientists
employees in the 25-40 year age bracket
PAT for FY20
of R&D and manufacturing infrastructure
Patents held with clients
capex investment
Technology has enabled us to build a streamlined, integrated organisation that delivers innovative research to support end-toend discovery, development and manufacturing services for our clients and partners.
In the past twelve months, we have delivered a strong business and operational performance, reflecting the strategic investments and focussed prioritisation of recent years.
Ensuring operational excellence as a way of life at Syngene is among our highest priorities. Every day we renew our commitment to ensure our processes are rigorous and our operating standards are world-class.
Our balance sheet position and underlying business fundamentals remain strong as we navigate through these challenging times and return to a more stable business environment. We are well-funded and financially secure and we will manage both operational and capital expenses prudently, and in a risk-managed way.
Watch Video
